Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 5:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 7,464 matching trials from the live ClinicalTrials.gov search.
Conditions
Cancer
Interventions
CGC-11047 and gemcitabine, CGC-11047 and docetaxel, CGC-11047 and bevacizumab, CGC-11047 and erlotinib, CGC-11047 and cisplatin, CGC-11047 and 5-flurouracil / leucovorin, CGC-11047 and sunitinib
Drug
Lead sponsor
Progen Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Denver, Colorado • Ocoee, Florida • Indianapolis, Indiana + 9 more
Conditions
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions
Azacitidine, Laboratory Biomarker Analysis, Lenalidomide, Vorinostat
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
280
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 217 more
Conditions
Contraception
Interventions
LNG20, Mirena
Drug
Lead sponsor
Medicines360
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
1,910 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
25
States / cities
Phoenix, Arizona • Palo Alto, California • San Francisco, California + 22 more
Conditions
Breast Cancer Female
Interventions
Presentation of personal breast cancer risk estimate
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
39 Years to 74 Years · Female only
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • St Louis, Missouri
Conditions
Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma, Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Soft Tissue Sarcoma, Metastatic Bone Sarcoma, Metastatic Liposarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Unresectable Sarcoma, Pleomorphic Liposarcoma, Stage III Bone Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Bone Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Bone Sarcoma AJCC v7, Stage IVB Bone Sarcoma AJCC v7, Unresectable Bone Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Liposarcoma, Unresectable Malignant Gastrointestinal Stromal Tumor, Unresectable Soft Tissue Sarcoma
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
651
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 402 more
Conditions
Lymphoma, Nonneoplastic Condition
Interventions
bleomycin sulfate, filgrastim, ABVD regimen, BEACOPP regimen, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, prednisone, procarbazine hydrochloride, vinblastine sulfate, vincristine sulfate
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 60 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
423
States / cities
Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 290 more
Conditions
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
Interventions
Atrasentan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
14
States / cities
Glendale, California • Los Angeles, California • San Dimas, California + 11 more
Conditions
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease
Interventions
Dasatinib, Imatinib Mesylate, Laboratory Biomarker Analysis, Nilotinib, Pembrolizumab
Drug · Other · Biological
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
291
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 209 more
Conditions
Breastfeeding
Interventions
Telephone Support Intervention to Improve Breastfeeding
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Pemigatinib, Computed Tomography (CT), Magnetic Resonance Imaging, Optical Coherence Tomography, Bone Scan, Ophthalmoscopy
Drug · Procedure
Lead sponsor
Sameek Roychowdhury
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
109
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 106 more
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Bevacizumab, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Osimertinib
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
604
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 426 more
Conditions
Rheumatoid Arthritis
Interventions
MM-093
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
20
States / cities
Montgomery, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 16 more
Conditions
HIV-1 Infection
Interventions
ISL, LEN, B/F/TAF, ISL/LEN FDC
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
44
States / cities
Beverly Hills, California • Los Angeles, California • Newport Beach, California + 33 more
Conditions
Lymphatic Malformations, Lymphatic Diseases
Interventions
Sildenafil 20 mg tablets, Placebo tablets (resembling Revatio)
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 10 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Chicago, Illinois
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
Oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Conditions
Major Depressive Disorder
Interventions
Trazodone Hydrochloride (HCl) Extended-Release Tablets, Placebo
Drug
Lead sponsor
Labopharm Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
28
States / cities
Birmingham, Alabama • Mesa, Arizona • Beverly Hills, California + 25 more
Conditions
Depression, Anxiety
Interventions
Meru Health Program, Treatment as Usual
Behavioral
Lead sponsor
Meru Health, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
10 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
5
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Boston, Massachusetts + 2 more
Conditions
Type 2 Diabetes
Interventions
ertugliflozine, low salt diet, placebo, high salt diet
Drug · Behavioral
Lead sponsor
Amsterdam UMC, location VUmc
Other
Eligibility
18 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate, Efavirenz, Nevirapine, Lamivudine, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 13 more
Conditions
Asthma
Interventions
formoterol
Device
Lead sponsor
Novartis
Industry
Eligibility
5 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
12
States / cities
Huntington Beach, California • San Diego, California • San Jose, California + 8 more
Conditions
Infusion Reactions
Interventions
unlicensed CBU
Biological
Lead sponsor
New York Blood Center
Other
Eligibility
Not listed
Enrollment
9,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Conditions
Advanced Solid Tumors
Interventions
intravenous (IV) infusion
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
11
States / cities
Denver, Colorado • New Haven, Connecticut • Lake Mary, Florida + 8 more
Conditions
Cutaneous Common Warts
Interventions
CLS006, CLS006 Vehicle
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
2 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Hot Springs, Arkansas • Oceanside, California • San Diego, California + 30 more